Metastatic properties of prostate cancer cells are controlled by VEGF

Cell Communication and Adhesion

Volumn 11, Issue 1, 2004, Pages 1-11

  Chen, Juhua ^a   De, Sarmishtha ^a   Brainard, Jennifer ^a   Byzova, Tatiana V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Extracellular matrix; Fibronectin; Integrin; Prostate cancer; VEGF

Indexed keywords

ALPHA5 INTEGRIN; BETA1 INTEGRIN; FIBRONECTIN; LIGAND; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SIALOPROTEIN; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; REGULATORY MECHANISM;

BONE NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA5BETA1; MALE; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; PHOSPHORIC MONOESTER HYDROLASES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 4043157141     PISSN: 15419061     EISSN: None     Source Type: Journal    
DOI: 10.1080/15419060490471739     Document Type: Article

References (42)

1. Bellahcene A, Antoine N, Clausse N, Tagliabue E, Fisher LW, Kerr JM, Jares P, Castronovo V (1996a). Detection of bone sialoprotein in human breast cancer tissue and cell lines at both protein and messenger ribonucleic acid levels. Lab Invest 75: 203-210.
2. Bellahcene A, Kroll M, Liebens F, Castronovo V (1996b). Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 11: 665-670.
3. Bloch W, Forsberg E, Lentini S, Brakebusch C, Martin K, Krell HW, Weidle UH, Addicks K, Fassler R (1997). Beta 1 integrin is essential for teratoma growth and angiogenesis, J Cell Biol 139: 265-278.
4. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE (2000). Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60: 5117-5124.
5. Byzova T V, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, Siemionow M, Deitcher SR, DiCorleto PE (2002). Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood 99: 4434-4442.
6. Byzova TV, Goldman CK, Pampori N, Thomas KA, Bett AJ, Shattil SJ, Plow EF (2000a). A Mechanism for Modulation of Cellular Responses to VEGF: Activation of the Integrins. Mol Cell 6(4): 851-860.
7. Byzova TV, Kim W, Midura RJ, Plow EF (2000b). Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res 254: 299-308.
8. 3 on vascular cells controls recognition of prothrombin. J Cell Biol 143: 2081-2092.
9. Cher ML (2001). Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 11: 483-488.
10. Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS (1992). Human prostate cancer model: Roles of growth factors and extracellular matrices. J Cell Biochem Suppl 16H: 99-105.
11. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE (2002). Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 8(6): 1904-1914.
12. De S, Chen J, Narizhneva NV, Heston W, Brainard J, Sage EH, Byzova TV (2003). Molecular pathway for cancer metastasis to bone. J Biol Chem 278: 39044-39050.
13. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S (2000). Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106: 511-521.
14. Fata JE, Werb Z, Bissell MJ (2004). Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res 6: 1-11.
15. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL (1997). Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells [see comments]. J Urol 157: 2329-2333.
16. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL (1998). Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51: 161-167.
17. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL (1999). Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54: 567-572.
18. Folkman J (1997). Angiogenesis and angiogenesis inhibition: An overview. EXS 79: 1-8.
19. Folkman J (1998). Antiangiogenic gene therapy. Proc Natl Acad Sci USA 95: 9064-9066.
20. Gardiner EE, D'Souza SE (1997). A mitogenic action for fibrinogen mediated through intercellular adhesion molecule-1. J Biol Chem 272: 15474-15480.
21. Giri D, Ittmann M (1999). lnactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 30: 419-424.
22. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LW (1992). Prostate and bone fibroblasts induce human prostate cancer growth in vivo: Implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 147: 1151-1159.
23. Hynes RO (1992). Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25.
24. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, Harris AL (2000). Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 85: 276-280.
25. Juliano RL, Varner JA (1993). Adhesion molecules in cancer: The role of integrins. Curr Opin Cell Biol 5: 812-818.
26. Koeneman KS, Yeung F, Chung LW (1999). Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39(4): 246-261.
27. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS (2001). Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98: 1904-1913.
28. Mintz KP, Grzesik WJ, Midura RJ, Robey PG, Termine JD, Fisher LW (1993). Purification and fragmentation of nondenatured bone sialoprotein: Evidence for a cryptic, RGD-resistant cell attachment domain. J Bone Miner Res 8:985-995.
29. Mori A, Arii S, Furutani M, Mizumoto M, Uchida S, Furuyama H, Kondo Y, Gorrin-Rivas MJ, Furumoto K, Kaneda Y, Imamura M (2000). Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther 7: 1027-1033.
30. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF (1997). Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 385: 537-540.
31. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW (2000). Ligand binding to integrins. J Biol Chem 275: 21785-21788.
32. Reiss K, Wang JY, Romano G, Tu X, Peruzzi F, Baserga R (2001). Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells. Oncogene 20: 490-500.
33. Roach HI (1994). Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption. Cell Biol Int 18:617-628.
34. Ruoslahti E (1996). Integrin signaling and matrix assembly. Tumour Biol 17: 117-124.
35. Sciavolino PJ, Abate-Shen C (1998). Molecular biology of prostate development and prostate cancer. Ann Med 30: 357-368.
36. Smit JW, van der PG, Vloedgraven HJ, Lowik CW, Goslings BM (1998). Role of integrins in the attachment of metastatic follicular thyroid carcinoma cell lines to bone. Thyroid 8:29-36.
37. SokoloffMH, Chung LW (1998). Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Cancer Metastasis Rev 17:307-315.
38. 5 integrins. J Cell Physiol 176: 482-494.
39. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW (1994). Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer [published erratum appears in Cancer Res 54(14):3953]. Cancer Res 54: 2577-2581.
40. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J, Castronovo V (1998). Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer, J Natl Cancer Inst 90: 1000-1008.
41. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409.
42. Zhau HE, Li CL, Chung LW (2000). Establishment of human prostate carcinoma skeletal metastasis models. Cancer 88: 2995-3001.